Retatrutide and trizepatide constitute a new class of medications that target both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. These multifunctional receptor https://mariahmkev803199.wikifrontier.com/user